Semaglutide Pen

DRUG3 trials

Sponsors

Eli Lilly and Company, Popular Medical College Hospital, Unity Health Toronto

Conditions

DiabetesDiabetes Mellitus, Type 2DialysisEnd Stage Kidney Disease (ESRD)Kidney Disease, ChronicObesityType 2 Diabetes Mellitus (T2DM)

Phase 3

Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus

Not yet recruitingNCT06616961

Popular Medical College HospitalObesity, Type 2 Diabetes Mellitus (T2DM)

Start: 2024-11-01End: 2026-10-31Target: 480Updated: 2024-09-27

Phase 4

A Study Comparing the Dulaglutide Pen and the Semaglutide Pen

CompletedNCT03724981

Eli Lilly and CompanyDiabetes Mellitus, Type 2

Start: 2018-10-18End: 2019-04-12Updated: 2020-04-24

Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

RecruitingNCT07017270

Unity Health TorontoDiabetes, Dialysis, End Stage Kidney Disease (ESRD) +1

Start: 2025-11-27End: 2027-09-01Target: 100Updated: 2026-06-26